Novartis Refuses To Yank Gleevec Lawsuit

Law360, New York (March 6, 2007, 12:00 AM EST) -- Standing strong in the face of international pressure, Novartis AG has refused to withdraw its controversial Gleevec lawsuit in India but has slightly modified its stance against a key section of the country’s patent laws.

In arguments in the Madras High Court on Monday, the drug maker said the company was not opposed to Section 3(d) of India’s Patents Amendment Act in its entirety, but rather to its interpretation, Daily News & Analysis reported.

The pharmaceutical giant had previously lobbied the court to declare Section 3(d)—which...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.